Abbott has announced the launch of the new DRG Invisible Trial System, approved by the US Food and Drug Administration (FDA) and received CE Mark in Europe.
People suffering from complex chronic pain conditions can now use the DRG Invisible Trial System to try Abbott’s dorsal root ganglion (DRG) stimulation—it’s clinically proven, non-opioid treatment option for targeted chronic pain management.
Patients who are relieved with DRG therapy can then have Abbott’s Proclaim DRG system implanted, it empowers them to manage their pain with familiar Apple consumer technology.
